DHT Holdings, Inc. has filed Form 20-F for 2024 with the U.S. Securities and Exchange Commission
HAMILTON, BERMUDA, March 20, 2025 – DHT Holdings, Inc. (NYSE:DHT) (the “Company”) has filed its 2024 annual report on Form 20-F with […]
BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025
MELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage […]
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming […]
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for […]
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective […]
Jaime Sayre Kawaja Returns to Kentucky to Lead Gray’s Stations in the Lexington/Hazard Market
ATLANTA, March 20, 2025 (GLOBE NEWSWIRE) — Gray Media has named Jaime Sayre Kawaja as General Manager and Director of […]
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company […]
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company […]
EXL to Host Investor Strategy Update Event on May 6 in New York
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) — ExlService Holdings, Inc. (NASDAQ: EXLS), a global data and AI company, today […]
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a […]
